Ignite Creation Date:
2024-07-17 @ 11:13 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06501339
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2023-10-14
Brief Title:
Maintenance Electroconvulsive Therapy ECT Versus Aripiprazole in Clozapine-resistant Schizophrenia
Sponsor:
All India Institute of Medical Sciences Bhubaneswar
Organization:
All India Institute of Medical Sciences Bhubaneswar
Study Overview
Official Title:
Maintenance Electroconvulsive Therapy ECT Versus Aripiprazole on Psychopathology and Cerebral Perfusion in Clozapine-resistant Schizophrenia a Randomized Double-blind Controlled Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited Few studies have found ECT as beneficial in TRS including CRS However literature on the role of M-ECT in maintaining the therapeutic gains of acute ECT in CRS is lacking The objective of the study is to compare the efficacy of M-ECT vs aripiprazole as an add-on to ongoing clozapine on the severity of symptom dimensions cerebral perfusion global functioning and cognitions in patients with CRS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None